These results indicate that PFAS and PAH likely activate different molecular mechanisms in steatosis adverse outcome pathways and, while the mechanism is similar among the PFAS, the magnitude of the alteration likely depends on the PFAS chain length and functional group. The gene discussed is PFAS; the disease is steatosis.